1. Introduction to the Project

1.1 Introduction to technical achievements

The project technology mainly provides services for the tumor organoid drug sensitivity testing platform for scientific research and clinical precision treatment, commercialization and production of the upstream, midstream, and downstream products in the industry, and in-vitro CRO for new drug research and development; it is dedicated to personalized treatment, new drug development, and basic medical research, with a complete industry chain of organoids. It aims to build an international organoid industry base.

1.2 Technical analysis and advantages

With organoids as an emerging 3D primary culture technology, the cultivated “micro-organs” can simulate the in-vivo environment well and have great application prospects in some fields such as tumor molecular mechanism research and drug screening.

The organoid technology of the project team has greatly shortened the screening time for cancer treatment drugs, shortening the research and development cycle for new drug development institutions and reducing research and development costs by more than 50%.

1.3 Main products and applications of technical achievements

(1) Tumor organoid sample libraries: tumor organoid biological sample library, anti-tumor active substance resource library

(2) Clinical medical services: autologous tumor tissue storage, tumor organoid drug sensitivity testing

(3) Pharmaceutical services: new drug development (in-vitro CRO), drug safety evaluation, and evaluation of anti-tumor performance of authentic Chinese medicinal materials in Changbai Mountain

(4) Organoid chips

1.4 Technical achievement commercialization and market promotion

1.4.1 Stage of technological achievements

It is seeking social capital cooperation to enter the industrialization stage.

1.4.2 Technical achievement marketing promotion plan

The main target market of the project is:

(1) Research institutions: Researchers in some fields such as biology, pharmacology, and medicine need to screen and study the mechanisms of tumor organoid drugs.

(2) Pharmaceutical enterprise: New drug research and development department, using tumor organoid models for drug screening and early clinical trials.

(3) Medical institutions: Oncologists who require personalized treatment and precise medication guidance.

Main promotion strategies:

(1) Market research: Understand the needs and pain points of target customers, as well as the service content and price level in the same industry.

(2) Brand building: Enhance awareness and influence in the field of precision medicine through academic conferences, seminars, collaborative research, and other means.

(3) Online promotion: Utilize official websites, social media, industry forums and other channels to publish project related information and service content, and attract potential customers.

(4) Offline promotion: Participate in academic conferences, exhibitions, and other activities, communicate face-to-face with potential customers, understand their needs, and provide solutions.

(5) Collaborative promotion: Collaborate with research institutions, pharmaceutical companies, medical institutions, etc. to jointly carry out research projects and expand market share.

(6) Training and support: Provide professional technical training and customer support to ensure that customers can fully utilize platform resources and improve research efficiency.

1.5 Technical team

The project was founded by the research team led by Academician Ding Jian. The team is the one consisting of experts and Ph.D. led by the academicians of the Chinese Academy of Sciences. The team is supported by the clinical expert teams from the First Hospital, Second Hospital, and China-Japan Union Hospital of Jilin University; Dr. Liu Zhengrui, a Ph.D. in pharmacology from China Pharmaceutical University, served as the main project leader; Dr. Sun Li serves as the technical leader, responsible for model construction and formulation of drug evaluation strategies; Dr. Sun Yang serves as the research and development leader, responsible for the research and development of bioactive substances and high-throughput screening technologies.

2. Market Potential Analysis

Cancer is a serious disease that poses a threat to human health worldwide, and precise medication has always been a core issue that troubles many doctors and patients. Over the past few decades, most preclinical studies of drugs have been conducted on 2D cell culture models, but increasing evidence suggests that 3D cell culture can better reproduce the in vivo environment of tumors and is more clinically representative. The commercialization of tumor in vitro culture models from 2D to 3D is the bottleneck and key technical pain point in overcoming precise tumor treatment.

Tumor-like organs are ex-vivo three-dimensional models directly derived from the patient’s tumor tissues, which have been proven to be highly consistent with the pathological, molecular, and drug sensitivity characteristics of the patient’s tumor. Meanwhile, due to their high accuracy in predicting a patient’s efficacy through drug sensitivity, they have received widespread attention and clinical application exploration from experts worldwide.The application of organoids in new drug development started relatively late, but the regulatory and industrial promotion efforts are increasing. In the past two years, the Ministry of Science and Technology, the National Health Commission, and the CDE have continuously introduced policies to loosen the restrictions on the widespread use of organoids. At the same time, the supervision of human heritage resources has gradually tightened, creating a broader development environment for the domestic organoid industry. At present, some companies such as WuXi AppTec, Hengrui Pharmaceutical Co., Ltd., and BGNE have applied organoid technology to new drug research and development. In addition, multinational pharmaceutical companies such as Merck and Roche have also expanded their China Innovation Center projects to the field of organoids.

From the overall development situation, whether it is organoid models or organ chips, China is still in its early stages. Technically, it is necessary to further improve throughput and address accuracy and repeatability issues; in terms of business models, it is necessary to further explore the potential of organoid applications.

As a new detection technology in the era of precision medicine, tumor organoid drug sensitivity testing is still in its early stages to guide patients in drug selection. The application scenarios of tumor organoid drug sensitivity testing are not fixed, and the application scenarios of tumor organoid drug sensitivity testing vary from person to person. In the future, with the continuous improvement of this technology and the increasing understanding of physicians and patients in this field, its application may become more and more widespread. In addition, after successful in-vitro tumor organoid culture, clinical physicians can determine the drugs or drug combinations to be prioritized for testing based on a comprehensive assessment of the patient's tumor and treatment status, thereby providing reference for patient medication selection.

The precision medical service platform project for tumor organoids is a challenging and promising medical research project that will help promote the development of tumor research and treatment, and provide better medical services for patients.

3. Financing Needs and Financing Purposes

The project is planned to raise 5 million yuan for the establishment of a tumor sample library and the collection of organoid samples; the various expenses for project implementation, including but not limited to equipment and consumables procurement, personnel salaries, etc.

4. Analysis of Technical Achievements and Benefits

4.1 Economic benefits

The market valuation of the project’s technical achievements is 95 million yuan.

4.2 Social benefits

The industrialization of the project technology will improve diagnostic accuracy and provide stronger support for clinical treatment; it will provide personalized treatment plans based on individual differences of patients. This helps to increase the success rate of treatment and improve the quality of life of patients. Doctors can choose treatment plans more accurately, avoid unnecessary drugs and treatment attempts, and thus reduce the medical costs of patients. At the same time, it can provide a large amount of valuable data for medical research, promote the progress of medical research, provide new ideas and methods for disease prevention and treatment, promote the progress of medical science, and improve the health literacy of the whole population.

5. Contact Method:

Contact person: Liu Zhengrui

Tel: 15618277705